Rapid resolution of symptoms with ciprofloxacin therapy in 3859 hospitalised patients with urinary tract infection

International Journal of Antimicrobial Agents

Volumn 23, Issue SUPPL. 1, 2004, Pages 35-40

  Naber, K G ^a   Landen, H ^b  

^a Urologische Klinik   (Germany)

^b BAYER AG   (Germany)

Author keywords

Ciprofloxacin; Post marketing surveillance; Urinary tract infection

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; ALLERGIC REACTION; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MARKETING; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

EID: 1642385257     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.010     Document Type: Conference Paper

References (19)

1. Gastmeier P., Kampf G., Wischnewski N.et al. Prevalence of nosocomial infections in representative German hospitals. J. Hosp. Infect. 38:1998;37-49.
2. Urinary tract infection (UTI) working group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Eur Urol 2001;40:576-88.
3. Naber K.G. Rationale Diagnostik und Therapie von Harnwegsinfektionen (Rational diagnosis and therapy of infections of the urinary tract). Urologe. 37:1997;328-334.
4. Naber K.G. Are the fluoroquinolones comparable in the treatment of urinary tract infections? Drugs. 58:1999;330-334.
5. Naber K.G., Fünfstück R., Hofstetter A.et al. Empfehlungen zur antimikrobiellen therapie von infektionen der nieren und des urogenitaltraktes bei erwachsenen. Chemother. J. 6:2000;193-199.
6. Kalsi J., Arya M., Wilson P., Mundy A. Hospital-acquired urinary tract infection. Int. J. Clin. Pract. 57:2003;388-391.
7. Schaeffer A.J. The expanding role of fluoroquinolones. Dis. Mon. 49:2003;129-147.
8. Iravani A., Tice A.D., McCarty J.et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infections in women. The minimum effective dose. Arch. Intern. Med. 155:1995;485-494.
9. McCarty J.M., Richard G., Huck W.et al. A randomised trial of short-course ciprofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Am. J. Med. 106:1999;292-299.
10. Frankenschmidt A., Naber K.G., Bischoff W., Kullmann K. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. J. Urol. 158:1997;1494-1499.
11. Mombelli G., Pezzoli R., Pinoja-Lutz G., Monatti R., Marone C., Franciolli M. Oral vs. intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections. Arch. Intern. Med. 159:1999;53-58.
12. Krcmery S., Naber K.G. German Ciprofloxacin UTI Study Group Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. Int. J. Antimicrob. Agents. 11:1999;133-138.
13. Harding G., Nicolle L., Wenman W.et al. Randomised comparison of oral ciprofloxacin vs. standard parenteral therapy in the treatment of complicated urinary tract infections. Drugs. 45:1993;333-334.
14. Raz R., Naber K.G., Raizenberg C.et al. Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women. Eur. J. Microbiol. Infect. Dis. 19:2000;327-331.
15. Naber K.G., Theuretzbacher U., Moneva-Koucheva G., Stass H. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;783-789.
16. Landen H., Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia: results of a post-marketing surveillance study. Clin. Drug Invest. 21:2001;801-808.
17. Ulleryd P., Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomised trial with a 1 year follow-up. Scand. J. Infect. Dis. 35:2003;34-39.
18. Fang G., Brennen C., Wagener M.et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomiized clinical and pharmacokinetic study. Antimicrob. Agents Chemother. 35:1991;1849-1855.
19. Blondeau J.M. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Exp. Opin. Invest. Drugs. 10:2001;213-237.